These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 21616175

  • 1. Vaccine candidates for leishmaniasis: a review.
    Nagill R, Kaur S.
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Leishmaniasis.
    Kedzierski L.
    Hum Vaccin; 2011 Nov; 7(11):1204-14. PubMed ID: 22048116
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Progress towards a Leishmania vaccine.
    Tabbara KS.
    Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, Larraga V.
    Vaccine; 2008 Jan 17; 26(3):333-44. PubMed ID: 18093705
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R, Kaur S.
    Vaccine; 2010 May 21; 28(23):4002-12. PubMed ID: 20093205
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L.
    Vaccine; 2007 May 22; 25(21):4159-69. PubMed ID: 17395340
    [Abstract] [Full Text] [Related]

  • 17. The immunology of Leishmania infection and the implications for vaccine development.
    Vanloubbeeck Y, Jones DE.
    Ann N Y Acad Sci; 2004 Oct 22; 1026():267-72. PubMed ID: 15604504
    [Abstract] [Full Text] [Related]

  • 18. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK, Mbati PA, Anjili CO, Orago AS, Turco SJ, Githure JI, Koech DK.
    East Afr Med J; 2001 Feb 22; 78(2):90-2. PubMed ID: 11682953
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT, Vale AM, França da Silva JC, da Costa RT, Quetz Jda S, Martins Filho OA, Reis AB, Corrêa Oliveira R, Machado-Coelho GL, Bueno LL, Bethony JM, Frank G, Nascimento E, Genaro O, Mayrink W, Reed S, Campos-Neto A.
    Vet Res; 2005 Feb 22; 36(5-6):827-38. PubMed ID: 16120256
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.